# EDGAR Filing Document

**Accession Number:** 0002023311
**File Stem:** 0001213900-25-073669
**Filing Date:** 2025-8
**Character Count:** 4094
**Document Hash:** 91c053769bf4b903e4cd55fa1988cc83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-073669.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001213900-25-073669

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250808

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASCENTAGE PHARMA GROUP INTERNATIONAL
- **CENTRAL INDEX KEY:** 0002023311
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42484
- **FILM NUMBER:** 251198588

**BUSINESS ADDRESS:**
- **STREET 1:** 68 XINQING ROAD
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** SUZHOU , JIANGSU
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 512 8555 7777

**MAIL ADDRESS:**
- **STREET 1:** 68 XINQING ROAD
- **STREET 2:** SUZHOU INDUSTRIAL PARK
- **CITY:** SUZHOU , JIANGSU
- **STATE:** F4
- **ZIP:** 00000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Form 6-K** 

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**under the Securities Exchange Act of 1934**

For the month of **August 2025**

**Commission File Number: 001-42484**

**ASCENTAGE PHARMA GROUP INTERNATIONAL**

*(Translation of Registrant's name into English)*

**68 Xinqing Road**

**Suzhou Industrial Park**

**Suzhou, Jiangsu**

**China**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On August 8, 2025, Ascentage Pharma Group International posted an announcement on the Hong Kong Stock Exchange entitled, "Notice of Board Meeting". A copy of the announcement is furnished as Exhibit 99.1 to this Report.

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit Title** |
| 99.1 | [Announcement dated August 8, 2025](ea025244901ex99-1_ascentage.htm)<br>|

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **ASCENTAGE PHARMA GROUP INTERNATIONAL** |
| Date: August 8, 2025 | */s/ Dajun Yang* |
|  | Name: Dajun Yang |
|  | Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

 

![](image_003.jpg)

**ASCENTAGE PHARMA GROUP INTERNATIONAL**

**亞盛醫藥集團**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

**NOTICE OF BOARD MEETING**

The board of directors (the "**Board**") of Ascentage Pharma Group International (the "**Company**", together with its subsidiaries, collectively the "**Group**") hereby announces that a meeting of the Board will be held on Wednesday, August 20, 2025, for the purpose of, among other things, considering and, if appropriate, approving the unaudited interim results of the Group for the six months ended June 30, 2025 and its publication.

By order of the Board

**Ascentage Pharma Group International Dr. Yang Dajun**

*Chairman and Executive Director*

 

Suzhou, People's Republic of China, August 8, 2025

*As at the date of this announcement, the Board comprises Dr. Yang Dajun as chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.*